Iopanoic acid
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C11H12I3NO2 |
Molar mass | 570.93 g/mol |
3D model (JSmol) | |
| |
|
WikiDoc Resources for Iopanoic acid |
Articles |
---|
Most recent articles on Iopanoic acid Most cited articles on Iopanoic acid |
Media |
Powerpoint slides on Iopanoic acid |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Iopanoic acid at Clinical Trials.gov Trial results on Iopanoic acid Clinical Trials on Iopanoic acid at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Iopanoic acid NICE Guidance on Iopanoic acid
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Iopanoic acid Discussion groups on Iopanoic acid Patient Handouts on Iopanoic acid Directions to Hospitals Treating Iopanoic acid Risk calculators and risk factors for Iopanoic acid
|
Healthcare Provider Resources |
Causes & Risk Factors for Iopanoic acid |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Iopanoic acid is an iodine-containing radiocontrast medium used in cholecystography. Both iopanoic acid and ipodate sodium are potent inhibitors of thyroid hormone release from thyroid gland, as well as of peripheral conversion of thyroxine (T4) to triiodothyronine (T3). These compounds inhibit 5'deiodinase (5'DID-1 and 5'DID-2) enzymes, which catalyse T4-T3 conversion in the thyroid cell, liver, kidney, skeletal muscle, heart, brain, pituitary. This accounts for the dramatic improvement in both subjective and objective symptoms of hyperthyroidism, particularly when they are used as an adjunctive therapy with thioamides (propylthiouracil, carbimazole). These are less toxic, as iodine is covalently bound in these compounds. They can be used in the treatment of patients with severe thyrotoxicosis (thyroid storm) and significant morbidity (e.g., myocardial infarction, or stroke) for rapid control of elevated plasma triiodothyronine concentrations. The use of iopanoic acid for treatment of thyrotoxicosis has been discontinued in the United States.
In addition to inhibiting deiodinase enzymes, iopanoic acid is also a substrate of type 1 deiodinase. Iopanoic acid underwent monodeiodination in the presence of type 1 deiodinase in a microsomal mouse liver preparation.[1]
References
- ↑ Renko, K.; Hoefig, C. S.; Hiller, F.; Schomburg, L.; Kohrle, J. (20 March 2012). "Identification of Iopanoic Acid as Substrate of Type 1 Deiodinase by a Novel Nonradioactive Iodide-Release Assay". Endocrinology. 153 (5): 2506–2513. doi:10.1210/en.2011-1863.
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- Articles with changed DrugBank identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drug
- Radiocontrast agents
- Organoiodides